NBIX logo

Neurocrine Biosciences, Inc. (NBIX) Cash From Financing

Annual CFF:

-$486.70M-$552.00M(-845.33%)
December 31, 2024

Summary

  • As of today, NBIX annual cash from financing is -$486.70 million, with the most recent change of -$552.00 million (-845.33%) on December 31, 2024.
  • During the last 3 years, NBIX annual cash from financing has fallen by -$514.10 million (-1876.28%).
  • NBIX annual cash from financing is now -194.20% below its all-time high of $516.65 million, reached on December 31, 2017.

Performance

NBIX Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNBIXcash flow metrics

Quarterly CFF:

-$3.30M+$114.60M(+97.20%)
June 30, 2025

Summary

  • As of today, NBIX quarterly cash from financing is -$3.30 million, with the most recent change of +$114.60 million (+97.20%) on June 30, 2025.
  • Over the past year, NBIX quarterly cash from financing has increased by +$289.70 million (+98.87%).
  • NBIX quarterly cash from financing is now -100.65% below its all-time high of $506.49 million, reached on June 30, 2017.

Performance

NBIX Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNBIXcash flow metrics

TTM CFF:

-$384.80M+$289.70M(+42.95%)
June 30, 2025

Summary

  • As of today, NBIX TTM cash from financing is -$384.80 million, with the most recent change of +$289.70 million (+42.95%) on June 30, 2025.
  • Over the past year, NBIX TTM cash from financing has dropped by -$215.90 million (-127.83%).
  • NBIX TTM cash from financing is now -172.43% below its all-time high of $531.25 million, reached on March 31, 2018.

Performance

NBIX TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNBIXcash flow metrics

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

NBIX Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-845.3%+98.9%-127.8%
3Y3 Years-1876.3%+98.8%-47.4%
5Y5 Years-1602.2%-120.9%-1071.7%

NBIX Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-845.3%at low-104.7%+98.9%-403.0%+43.0%
5Y5-Year-845.3%at low-104.7%+98.9%-403.0%+43.0%
All-TimeAll-Time-194.2%at low-100.7%+98.9%-172.4%+43.0%

NBIX Cash From Financing History

DateAnnualQuarterlyTTM
Jun 2025
-
-$3.30M(+97.2%)
-$384.80M(+43.0%)
Mar 2025
-
-$117.90M(+59.3%)
-$674.50M(-38.6%)
Dec 2024
-$486.70M(-845.3%)
-$290.00M(-1198.5%)
-$486.70M(-201.7%)
Sep 2024
-
$26.40M(+109.0%)
-$161.30M(+4.5%)
Jun 2024
-
-$293.00M(-519.2%)
-$168.90M(-233.0%)
Mar 2024
-
$69.90M(+97.5%)
$127.00M(+94.5%)
Dec 2023
$65.30M(+127.9%)
$35.40M(+88.3%)
$65.30M(+19.8%)
Sep 2023
-
$18.80M(+548.3%)
$54.50M(+15.7%)
Jun 2023
-
$2.90M(-64.6%)
$47.10M(+120.3%)
Mar 2023
-
$8.20M(-66.7%)
-$232.20M(+0.9%)
Dec 2022
-$234.30M(-955.1%)
$24.60M(+115.8%)
-$234.30M(+8.9%)
Sep 2022
-
$11.40M(+104.1%)
-$257.10M(+1.5%)
Jun 2022
-
-$276.40M(-4631.1%)
-$261.00M(-1518.5%)
Mar 2022
-
$6.10M(+238.9%)
$18.40M(-32.8%)
Dec 2021
$27.40M(+117.4%)
$1.80M(-76.0%)
$27.40M(+117.2%)
Sep 2021
-
$7.50M(+150.0%)
-$159.40M(+1.3%)
Jun 2021
-
$3.00M(-80.1%)
-$161.50M(-8.6%)
Mar 2021
-
$15.10M(+108.2%)
-$148.70M(+5.8%)
Dec 2020
-$157.80M(-587.0%)
-$185.00M(-3525.9%)
-$157.80M(-498.5%)
Sep 2020
-
$5.40M(-65.8%)
$39.60M(-16.3%)
Jun 2020
-
$15.80M(+163.3%)
$47.30M(+32.1%)
Mar 2020
-
$6.00M(-51.6%)
$35.80M(+10.5%)
Dec 2019
$32.40M(+9.8%)
$12.40M(-5.3%)
$32.40M(+49.0%)
Sep 2019
-
$13.10M(+204.7%)
$21.75M(+53.8%)
Jun 2019
-
$4.30M(+65.4%)
$14.14M(-11.4%)
Mar 2019
-
$2.60M(+48.4%)
$15.96M(-45.9%)
Dec 2018
$29.50M(-94.3%)
$1.75M(-68.1%)
$29.50M(-11.5%)
Sep 2018
-
$5.49M(-10.3%)
$33.35M(+8.0%)
Jun 2018
-
$6.12M(-62.1%)
$30.88M(-94.2%)
Mar 2018
-
$16.14M(+188.1%)
$531.25M(+2.8%)
Dec 2017
$516.65M(>+9900.0%)
$5.60M(+85.3%)
$516.65M(+1.1%)
Sep 2017
-
$3.02M(-99.4%)
$511.11M(+0.3%)
Jun 2017
-
$506.49M(>+9900.0%)
$509.42M(>+9900.0%)
Mar 2017
-
$1.53M(+2330.2%)
$3.86M(+61.5%)
Dec 2016
$2.39M(-99.1%)
$63.00K(-95.3%)
$2.39M(-27.5%)
Sep 2016
-
$1.33M(+42.0%)
$3.29M(+21.8%)
Jun 2016
-
$936.00K(+1409.7%)
$2.71M(-23.3%)
Mar 2016
-
$62.00K(-93.6%)
$3.53M(-98.7%)
Dec 2015
$276.99M(+99.7%)
$968.00K(+30.8%)
$276.99M(-0.3%)
Sep 2015
-
$740.00K(-57.9%)
$277.76M(+0.1%)
Jun 2015
-
$1.76M(-99.4%)
$277.50M(+0.5%)
Mar 2015
-
$273.52M(>+9900.0%)
$276.01M(+99.0%)
Dec 2014
$138.73M(+2516.6%)
$1.73M(+257.9%)
$138.73M(+1.2%)
Sep 2014
-
$484.00K(+76.6%)
$137.05M(-1.6%)
Jun 2014
-
$274.00K(-99.8%)
$139.23M(-1.0%)
Mar 2014
-
$136.24M(>+9900.0%)
$140.58M(+2551.4%)
Dec 2013
$5.30M(-93.7%)
$50.00K(-98.1%)
$5.30M(-4.3%)
Sep 2013
-
$2.66M(+63.8%)
$5.54M(+84.9%)
Jun 2013
-
$1.63M(+68.2%)
$3.00M(+111.8%)
Mar 2013
-
$966.00K(+235.4%)
$1.42M(-98.3%)
Dec 2012
$83.70M(>+9900.0%)
$288.00K(+144.1%)
$83.70M(+0.3%)
Sep 2012
-
$118.00K(+174.4%)
$83.44M(+0.1%)
Jun 2012
-
$43.00K(-99.9%)
$83.36M(-0.1%)
Mar 2012
-
$83.25M(>+9900.0%)
$83.48M(>+9900.0%)
Dec 2011
$286.00K(-98.7%)
$22.00K(-51.1%)
$286.00K(-21.2%)
Sep 2011
-
$45.00K(-72.2%)
$363.00K(+6.8%)
Jun 2011
-
$162.00K(+184.2%)
$340.00K(+87.8%)
Mar 2011
-
$57.00K(-42.4%)
$181.00K(-99.2%)
Dec 2010
$21.48M
$99.00K(+350.0%)
$21.48M(-31.3%)
DateAnnualQuarterlyTTM
Sep 2010
-
$22.00K(+633.3%)
$31.28M(+0.1%)
Jun 2010
-
$3000.00(-100.0%)
$31.26M(+0.0%)
Mar 2010
-
$21.36M(+115.7%)
$31.26M(+215.7%)
Dec 2009
$9.90M(+781.8%)
$9.90M(>+9900.0%)
$9.90M(+3700.0%)
Sep 2009
-
$0.00(0.0%)
-$275.00K(+54.2%)
Jun 2009
-
$0.00(0.0%)
-$600.00K(+39.5%)
Mar 2009
-
$0.00(+100.0%)
-$991.00K(+31.7%)
Dec 2008
-$1.45M(-102.5%)
-$275.00K(+15.4%)
-$1.45M(-102.5%)
Sep 2008
-
-$325.00K(+16.9%)
$58.94M(+1.3%)
Jun 2008
-
-$391.00K(+15.2%)
$58.19M(+0.5%)
Mar 2008
-
-$461.00K(-100.8%)
$57.88M(+1.2%)
Dec 2007
$57.18M(+466.9%)
$60.12M(+5702.8%)
$57.18M(+1500.8%)
Sep 2007
-
-$1.07M(-53.5%)
-$4.08M(+7.7%)
Jun 2007
-
-$699.00K(+40.0%)
-$4.42M(-25.1%)
Mar 2007
-
-$1.17M(-1.7%)
-$3.54M(-135.0%)
Dec 2006
$10.09M(-2.4%)
-$1.15M(+19.1%)
$10.09M(-45.5%)
Sep 2006
-
-$1.42M(-844.7%)
$18.50M(-22.7%)
Jun 2006
-
$190.00K(-98.5%)
$23.92M(+0.9%)
Mar 2006
-
$12.46M(+71.3%)
$23.71M(+129.5%)
Dec 2005
$10.33M(-71.8%)
$7.27M(+81.6%)
$10.33M(+344.8%)
Sep 2005
-
$4.00M(>+9900.0%)
$2.32M(-75.5%)
Jun 2005
-
-$19.00K(+97.9%)
$9.49M(-59.3%)
Mar 2005
-
-$922.00K(-24.6%)
$23.30M(-36.5%)
Dec 2004
$36.69M(-82.6%)
-$740.00K(-106.6%)
$36.69M(-29.7%)
Sep 2004
-
$11.17M(-19.0%)
$52.22M(-77.3%)
Jun 2004
-
$13.79M(+10.5%)
$230.16M(+5.0%)
Mar 2004
-
$12.47M(-15.6%)
$219.12M(+3.8%)
Dec 2003
$211.06M(+3532.1%)
$14.79M(-92.2%)
$211.06M(+6.0%)
Sep 2003
-
$189.11M(+6786.8%)
$199.03M(+1605.3%)
Jun 2003
-
$2.75M(-37.8%)
$11.67M(+13.8%)
Mar 2003
-
$4.41M(+60.2%)
$10.25M(+76.4%)
Dec 2002
$5.81M(-96.8%)
$2.75M(+56.9%)
$5.81M(-96.8%)
Sep 2002
-
$1.76M(+32.3%)
$182.06M(+1.1%)
Jun 2002
-
$1.33M(+5014.8%)
$180.17M(-0.4%)
Mar 2002
-
-$27.00K(-100.0%)
$180.88M(-0.2%)
Dec 2001
$181.30M(+92.6%)
$179.01M(>+9900.0%)
$181.30M(+93.6%)
Sep 2001
-
-$140.00K(-106.8%)
$93.65M(-1.7%)
Jun 2001
-
$2.05M(+423.3%)
$95.23M(+2.1%)
Mar 2001
-
$391.00K(-99.6%)
$93.30M(-0.9%)
Dec 2000
$94.13M(+129.6%)
$91.36M(+6275.2%)
$94.13M(+117.0%)
Sep 2000
-
$1.43M(+1114.4%)
$43.38M(+2.9%)
Jun 2000
-
$118.00K(-90.4%)
$42.14M(-0.4%)
Mar 2000
-
$1.22M(-97.0%)
$42.32M(+3.2%)
Dec 1999
$41.00M(+2057.9%)
$40.60M(>+9900.0%)
$41.00M(>+9900.0%)
Sep 1999
-
$200.00K(-33.3%)
$300.00K(-88.0%)
Jun 1999
-
$300.00K(+400.0%)
$2.50M(+31.6%)
Mar 1999
-
-$100.00K(0.0%)
$1.90M(0.0%)
Dec 1998
$1.90M(+171.4%)
-$100.00K(-104.2%)
$1.90M(-32.1%)
Sep 1998
-
$2.40M(+900.0%)
$2.80M(+833.3%)
Jun 1998
-
-$300.00K(-200.0%)
$300.00K(-40.0%)
Mar 1998
-
-$100.00K(-112.5%)
$500.00K(-28.6%)
Dec 1997
$700.00K(-98.5%)
$800.00K(+900.0%)
$700.00K(+333.3%)
Sep 1997
-
-$100.00K(0.0%)
-$300.00K(+25.0%)
Jun 1997
-
-$100.00K(-200.0%)
-$400.00K(-101.0%)
Mar 1997
-
$100.00K(+150.0%)
$42.10M(-10.0%)
Dec 1996
$46.80M
-$200.00K(0.0%)
$46.80M(-0.4%)
Sep 1996
-
-$200.00K(-100.5%)
$47.00M(-0.4%)
Jun 1996
-
$42.40M(+783.3%)
$47.20M(+883.3%)
Mar 1996
-
$4.80M
$4.80M

FAQ

  • What is Neurocrine Biosciences, Inc. annual cash from financing?
  • What is the all-time high annual cash from financing for Neurocrine Biosciences, Inc.?
  • What is Neurocrine Biosciences, Inc. annual cash from financing year-on-year change?
  • What is Neurocrine Biosciences, Inc. quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for Neurocrine Biosciences, Inc.?
  • What is Neurocrine Biosciences, Inc. quarterly cash from financing year-on-year change?
  • What is Neurocrine Biosciences, Inc. TTM cash from financing?
  • What is the all-time high TTM cash from financing for Neurocrine Biosciences, Inc.?
  • What is Neurocrine Biosciences, Inc. TTM cash from financing year-on-year change?

What is Neurocrine Biosciences, Inc. annual cash from financing?

The current annual cash from financing of NBIX is -$486.70M

What is the all-time high annual cash from financing for Neurocrine Biosciences, Inc.?

Neurocrine Biosciences, Inc. all-time high annual cash from financing is $516.65M

What is Neurocrine Biosciences, Inc. annual cash from financing year-on-year change?

Over the past year, NBIX annual cash from financing has changed by -$552.00M (-845.33%)

What is Neurocrine Biosciences, Inc. quarterly cash from financing?

The current quarterly cash from financing of NBIX is -$3.30M

What is the all-time high quarterly cash from financing for Neurocrine Biosciences, Inc.?

Neurocrine Biosciences, Inc. all-time high quarterly cash from financing is $506.49M

What is Neurocrine Biosciences, Inc. quarterly cash from financing year-on-year change?

Over the past year, NBIX quarterly cash from financing has changed by +$289.70M (+98.87%)

What is Neurocrine Biosciences, Inc. TTM cash from financing?

The current TTM cash from financing of NBIX is -$384.80M

What is the all-time high TTM cash from financing for Neurocrine Biosciences, Inc.?

Neurocrine Biosciences, Inc. all-time high TTM cash from financing is $531.25M

What is Neurocrine Biosciences, Inc. TTM cash from financing year-on-year change?

Over the past year, NBIX TTM cash from financing has changed by -$215.90M (-127.83%)
On this page